Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

Convertible Note Agreement | AC Immune SA, 11 December 201816/23

 

and correspond to the economic intent and purpose of such partly or entirely invalid or impractical provision and are valid and enforceable.

 

10.8.Waivers

 

No waiver by a Party of a failure of any other Party to perform any provision of this Note Agreement shall operate or be construed as a waiver with respect of any other or further failure.

 

10.9.Transfers or Assignments

 

The Company shall not transfer the Loan or assign any of its rights or obligations under the Loan or under this Note Agreement to any third party without the prior written consent of the Lender.

 

The Lender shall not transfer the Loan or the Note or assign any of its rights or obligations under the Loan, the Note or under this Note Agreement to any third party without the prior written consent of the Company.

 

10.10.Governing Law

 

This Note Agreement and any questions related thereto shall be subject to the laws of Switzerland excluding its conflict of law rules.

 

10.11.Arbitration

 

Any dispute, controversy or claim arising under, out of or relating to this Note Agreement (and subsequent amendments thereof), its valid conclusion, binding effect, interpretation, performance, breach or termination, including tort claims, shall be referred to and finally determined by arbitration in accordance with the rules set out in Section 13.5 (Dispute Resolution) of the License Agreement.

 

10.12.Termination

 

This Note Agreement will automatically and immediately terminate in the event that the License Agreement is terminated prior to the Closing Date.

 

 

[Remainder of this page intentionally left blank] 

 


© AC Immune 2015